

WHAT IS CLAIMED IS:

1. A composition comprising an immunogenic peptide having an HLA-A2.1 binding motif, which immunogenic peptide is selected from a group consisting of SEQ ID Nos: 1 through 191.
2. The composition of claim 1, wherein the immunogenic peptide has a sequence from hepatitis B virus and is SEQ ID NO:77.
3. The composition of claim 1, wherein the immunogenic peptide has a sequence from hepatitis C virus and is selected from the group consisting of SEQ ID Nos: 78-81.
4. The composition of claim 1, wherein the immunogenic peptide has a sequence from human immunodeficiency virus and is selected from the group consisting of SEQ ID Nos: 82-97.
5. The composition of claim 1, wherein the immunogenic peptide has a sequence from Her2/neu and is selected from the group consisting of SEQ ID Nos: 98-99.
6. The composition of claim 1, wherein the immunogenic peptide has a sequence from CEA and is selected from the group consisting of SEQ ID Nos: 100-106.
7. The composition of claim 1, wherein the immunogenic peptide has a sequence from p53 and is selected from the group consisting of SEQ ID Nos: 71-74.
8. The composition of claim 1, wherein the immunogenic peptide has a sequence from MAGE and is SEQ ID NO:70.

862020 SE 22 1053